ArticleArchives of microbiology2026
Disease-modifying efficacy of alginate-microencapsulated probiotics in an animal model of ulcerative colitis.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Ulcerative colitis (UC) can be challenging to control with current therapies. Modulating gut dysbiosis with probiotics is a promising approach, but the benefits depend on keeping the cell viability as they pass through gastrointestinal transit (GIT). This study developed an alginate microencapsulation system and evaluated its overall disease-modifying efficacy in an acetic acid-induced colitis model. Lactiplantibacillus plantarum and Levilactobacillus brevis were microencapsulated in calcium alginate beads via extrusion. Encapsulation efficiency, morphology, and viability under simulated GIT conditions were assessed. Forty-two male Wistar rats (non-colitic control; acetic acid-induced colitis) were gavaged for up to 12 days with normal saline, free or encapsulated probiotics, and/or mesalazine. Disease Activity Index (DAI), colon weight/length, histopathology, and colonic IFN-γ expression were measured; statistical significance was P < 0.05. Results displayed that encapsulation yielded a high efficiency (91.00% ± 1.69%). In simulated GIT conditions, Δ0-120 log CFU was significantly smaller for encapsulated than for free probiotics. Combination of encapsulated probiotics with mesalazine (EMT) showed the lowest weight loss score across all probiotic-based groups (p < 0.05). DAI declined from day 2 onward in most groups; by day 5, animals given encapsulated probiotics remained significantly different from non-colitic controls (p < 0.05). Histopathological assessment showed that either encapsulated or free probiotics significantly lower histopathological scores compared to the colitis group (p < 0.001), and real-time PCR revealed a significant difference between the EMT group compared to the colitis group (p < 0.05). Together, alginate-microencapsulated formulations were more effective than free probiotics with regard to outcome improvements, indicating a viable UC management strategy that needs further investigation.
Indexed as
Identifiers
41557026What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.